Last reviewed · How we verify
Secikinumab
Secikinumab is a Small molecule drug developed by The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School. It is currently in Phase 2 development. Also known as: AIN457.
Secikinumab is a medication used to treat conditions such as psoriasis and axial spondylarthritis. It is a biologic intervention that has been studied in clinical trials, including a registry of patients with moderate to severe plaque psoriasis in Canada and Latin America.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Secikinumab |
|---|---|
| Also known as | AIN457 |
| Sponsor | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Registry of Patients With Moderate to Severe Plaque Psoriasis
- Efficacy and Influencing Factors of Secukinumab in Patients With Axial Spondyloarthritis
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Secikinumab CI brief — competitive landscape report
- Secikinumab updates RSS · CI watch RSS
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School portfolio CI
Frequently asked questions about Secikinumab
What is Secikinumab?
Who makes Secikinumab?
Is Secikinumab also known as anything else?
What development phase is Secikinumab in?
Related
- Manufacturer: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School — full pipeline
- Therapeutic area: All drugs in Other
- Also known as: AIN457
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing